INCY Incyte Corporation

84.85
+1.52  (+2%)
Previous Close 83.33
Open 83.73
Price To Book 10.02
Market Cap 18056771358
Shares 212,808,148
Volume 1,202,285
Short Ratio
Av. Daily Volume 1,651,393

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met primary endpoint - February 4, 2019.
Baricitinib
Atopic dermatitis
Phase 2 interim data at ESMO October 2018. ORR 40%.
INCB54828 (FIGHT-202)
Cholangiocarcinoma
Phase 2 interim data released at ASH 2018.
INCB54828 (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Phase 2 data due 2019.
INCB54828 (FIGHT-201)
Bladder cancer
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Phase 3 data due 2H 2019.
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD
Phase 3 trial to be initiated in 2018.
Baricitinib
Psoriatic arthritis
Phase 2 trial to be discontinued - noted June 21, 2018.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal Phase 2 trial initiation announced November 15, 2017.
Ruxolitinib (RESET-272)
Essential thrombocythemia
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
PDUFA date under priority review extended by three months to May 24, 2019.
Ruxolitinib
Graft versus host disease
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 3 trial to commence 1H 2018.
Epacadostat with durvalumab
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-303)
Bladder cancer
Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients.
INC280
Non-small cell lung cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-307)
Bladder cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-304)
Head & neck cancer
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-309)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-310)
Head and neck cancer
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-306)
Non-small cell lung cancer (NSCLC)
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-305)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-302)
Renal cancer
Phase 1 oral abstract June 1, 2018, 2:45p.m. CT. Abstract 8005.
Ruxolitinib, Lenalidomide, and Methylprednisolone
Relapsed/Refractory Multiple Myeloma
Phase 1/2 ongoing.
INCB024360 + Epacadostat
Solid tumors
Phase 3 data due 2020.
Ruxolitinib - TRuE-AD
Atopic dermatitis
Phase 2 initial data due 2019.
INCB50465 (CITADEL-203)
Follicular lymphoma
Phase 2 initial data due 2019.
INCB50465 (CITADEL-204)
Marginal zone lymphoma
Phase 2 initial data due 2019.
INCB50465 (CITADEL-205)
Mantle cell lymphoma
Phase 1 data due 2021.
INCMGA0012
Anal cancer
Data due 2020.
INCMGA0012
Merkel cell carcinoma
Phase 1 data due 2020.
INCMGA0012
Endometrial cancer
Phase 1/2 initial data due 2019.
INCB53914 and ruxolitinib
Myelofibrosis and Solid Tumors
Phase 2 data presented at ASH December 2, 2018.
INCB50465 and ruxolitinib
Myelofibrosis
Phase 2 data due 2019.
Ruxolitinib
Vitiligo
Phase 1/2 data to be presented 1H 2019.
INCB001158
Solid tumors
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 commencement of dosing announced January 22, 2019.
Itacitinib - GRAVITAS-309
Chronic Graft-Versus-Host Disease

Latest News

  1. Looking For Growth? Take A Look At These Biotechnology Stocks
  2. Merck Gets Priority Review for Keytruda in Third-Line SCLC
  3. 6 Companies With 20% Or More Earnings Growth
  4. Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
  5. Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
  6. Incyte to Present at Upcoming Investor Conferences
  7. Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
  8. Incyte's Undervalued as Pipeline Progresses
  9. Edited Transcript of INCY earnings conference call or presentation 14-Feb-19 1:00pm GMT
  10. Incyte (INCY) Q4 2018 Earnings Conference Call Transcript
  11. Highly Rated Biotech Turns Profitable — But Earnings Lag Estimates
  12. Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
  13. Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored
  14. Incyte: 4Q Earnings Snapshot
  15. Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
  16. Incyte Earnings, Revenue beat in Q4
  17. Incyte Expected to Earn 17 Cents a Share
  18. Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
  19. Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica
  20. Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer